Study end-points
The primary study endpoint was TR progression (TR grade ≥3) and/or
abnormal TRPG levels (PG >30 mmHg). The secondary study
end-points were late-onset atrial fibrillation, HF hospitalization,
sudden death or ventricular tachyarrhythmias, cardiovascular mortality,
and all-cause mortality.